Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Incidence and risk factors for immune effector cell-associated neurotoxicity syndrome in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study

View Full Paper
Ask AI
Bookmark
Share

Authors

FSFrédérique St‐PierreANAlex NiuPJPatrick Johnston

Discussion

Loading...

Member takes

Overview

Multicenter study shows acceptable risk of neurotoxicity in older patients with relapsed B-cell lymphoma, suggesting need for careful candidate selection.

Key Points

  • This research aimed to assess the incidence and risk factors for neurotoxicity in older patients undergoing CART therapy for B-cell lymphoma.
  • Retrospective study across seven centers
  • Included patients aged ≥65 years with relapsed/refractory large B-cell lymphoma
  • Analyzed incidence and risk factors for ICANS using statistical methods
  • 30-day cumulative incidence of all grade ICANS was 50.9%
  • Higher incidence of grade ≥3 ICANS observed with increased ECOG performance status and elevated LDH
  • ICANS management included steroids and biologic agents, with varying outcomes based on prior treatment lines

Cite This Study

St‐Pierre et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d55fhttps://doi.org/10.1182/blood-2025-6310
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Neurotoxicity in older patients with relapsed or refractory large B-cell lymphoma treated with CAR T-cell therapy: A multicenter study2026
  2. 2ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study2026
  3. 3The cns-IPI score is predictive of severe immune effector cell-associated neurotoxicity after axicabtagene ciloleucel treatment in patients with large B-cell lymphoma2025
  4. 4Icans mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol – a pilot study2025
  5. 5P08.11.A MANAGEMENT OF IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME FOLLOWING CAR-T CELL THERAPY IN CLINICAL PRACTICE: A MULTICENTRIC, RETROSPECTIVE, REAL-WORLD ANALYSIS OF TREATMENT APPROACHES AND OUTCOMES2025